RxDoctor Payments Data

Kavitha Rao, MD

Infectious Disease · Topeka, KSNPI 1982717757

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $568 of the $638 with a category attached, or 89.0%. 8 manufacturers reported payments, led by Gilead at 37.0% of the total. Reporting peaked in 2019 at $456 and has fallen 95.0% since, to $23 in 2025.

$638in general payments, 2019–2025

Across 36 payments — averaging $17.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$236
  • Johnson & Johnson$116
  • Insmed, Inc.$85
  • Merck$73
  • Janssen Products, LP$70
  • Philips North America LLC$23
  • plus $36 from 2 others

What the payments were for

  • Food & beverage$56889%
  • Education$7011%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$638 in reported general payments places this provider in the 70th percentile of 56 infectious disease providers in Kansas.

See all infectious disease providers in Kansas

Medicare billing

Part B allowed, 2024
$159,595
Medicare patients
357
Services billed
1,719

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala53$237,046
OdefseyEmtricitab/Rilpiviri/Tenof Ala12$42,702
DovatoDolutegravir Sodium/Lamivudine12$40,547
PrezcobixDarunavir/Cobicistat13$31,356
TivicayDolutegravir Sodium11$24,335
Cefepime Hcl17$8,043
CeftriaxoneCeftriaxone Sodium38$5,720
Daptomycin22$4,374
Ampicillin Sodium14$3,650
Cefadroxil42$1,714
Doxycycline Hyclate37$1,102
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav31$637
Cephalexin26$486
Fluconazole13$386
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim22$166

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy$236$237,04653 claims
Johnson & JohnsonPrezcobix$116$31,35613 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 56 infectious disease providers in Kansas.

Other infectious disease in Topeka

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →